-
- Zhuoyan Li
- Department of Medicine Vanderbilt University Medical Center Nashville Tennessee
-
- Prerna Mewawalla
- Department of Hematology Western Pennsylvania Cancer Institute Pittsburgh Pennsylvania
-
- Pamela Stratton
- Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland
-
- Agnes S.M. Yong
- Department of Haematology, SA Pathology, and School of Medicine University of Adelaide Adelaide South Australia Australia
-
- Bronwen E. Shaw
- Center for International Blood and Marrow Transplant Research Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin
-
- Shahrukh Hashmi
- Division of Hematology Mayo Clinic Rochester Minnesota
-
- Madan Jagasia
- Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center and Veterans Affairs Medical Center Nashville Tennessee
-
- Mohamad Mohty
- INSERM (National Institute of Health and Medical Research) 938 Paris France
-
- Navneet S. Majhail
- Blood and Marrow Transplant Program Cleveland Clinic Cleveland Ohio
-
- Bipin N. Savani
- Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center and Veterans Affairs Medical Center Nashville Tennessee
-
- Alicia Rovó
- Department of Hematology University Hospital of Bern Bern Switzerland
抄録
<jats:p>Hematopoietic stem cell transplantation (HSCT) plays a central role in patients with malignant and, increasingly, nonmalignant conditions. As the number of transplants increases and the survival rate improves, long‐term complications are important to recognize and treat to maintain quality of life. Sexual dysfunction is a commonly described but relatively often underestimated complication after HSCT. Conditioning regimens, generalized or genital graft‐versus‐host disease, medications, and cardiovascular complications as well as psychosocial problems are known to contribute significantly to physical and psychological sexual dysfunction. Moreover, it is often a difficult topic for patients, their significant others, and health care providers to discuss. Early recognition and management of sexual dysfunction after HSCT can lead to improved quality of life and outcomes for patients and their partners. This review focuses on the risk factors for and treatment of sexual dysfunction after transplantation and provides guidance concerning how to approach and manage a patient with sexual dysfunction after HSCT. <jats:bold><jats:italic>Cancer</jats:italic> 2015;121:4124–4131.</jats:bold> © <jats:italic>2015 American Cancer Society</jats:italic>.</jats:p>
収録刊行物
-
- Cancer
-
Cancer 121 (23), 4124-4131, 2015-09-15
Wiley